

# Arthur J Matas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2374222/publications.pdf>

Version: 2024-02-01

394  
papers

21,686  
citations

8732

75  
h-index

12558

132  
g-index

400  
all docs

400  
docs citations

400  
times ranked

11434  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Consequences of Kidney Donation. <i>New England Journal of Medicine</i> , 2009, 360, 459-469.	13.9	1,168
2	Diabetes Mellitus after Kidney Transplantation in the United States. <i>American Journal of Transplantation</i> , 2003, 3, 178-185.	2.6	1,121
3	LRISK FACTORS FOR CHRONIC REJECTION IN RENAL ALLOGRAFT RECIPIENTS. <i>Transplantation</i> , 1993, 55, 752-756.	0.5	616
4	Lessons Learned From More Than 1,000 Pancreas Transplants at a Single Institution. <i>Annals of Surgery</i> , 2001, 233, 463-501.	2.1	576
5	DELAYED GRAFT FUNCTION, ACUTE REJECTION, AND OUTCOME AFTER CADAVER RENAL TRANSPLANTATION. <i>Transplantation</i> , 1995, 59, 962-968.	0.5	455
6	Evidence for Antibody-Mediated Injury as a Major Determinant of Late Kidney Allograft Failure. <i>Transplantation</i> , 2010, 90, 68-74.	0.5	447
7	Preemptive Kidney Transplantation: The Advantage and the Advantaged. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1358-1364.	3.0	424
8	IMMUNOPATHOLOGY OF HYPERACUTE XENOGRAFT REJECTION IN A SWINE-TO-PRIMATE MODEL. <i>Transplantation</i> , 1991, 52, 214-220.	0.5	418
9	Cell-Free DNA and Active Rejection in Kidney Allografts. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2221-2232.	3.0	365
10	Morbidity and Mortality After Living Kidney Donation, 1999-2001: Survey of United States Transplant Centers. <i>American Journal of Transplantation</i> , 2003, 3, 830-834.	2.6	302
11	LONG-TERM FOLLOW-UP OF LIVING KIDNEY DONORS: QUALITY OF LIFE AFTER DONATION <sup>1</sup> . <i>Transplantation</i> , 1999, 67, 717-721.	0.5	299
12	COMPLICATIONS AND RISKS OF LIVING DONOR NEPHRECTOMY <sup>1</sup> . <i>Transplantation</i> , 1997, 64, 1124-1128.	0.5	231
13	ARE WOUND COMPLICATIONS AFTER A KIDNEY TRANSPLANT MORE COMMON WITH MODERN IMMUNOSUPPRESSION?. <i>Transplantation</i> , 2001, 72, 1920-1923.	0.5	209
14	Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3353-3362.	3.0	204
15	Payment for Living Donor (Vendor) Kidneys: A Cost-Effectiveness Analysis. <i>American Journal of Transplantation</i> , 2004, 4, 216-221.	2.6	201
16	2,500 Living Donor Kidney Transplants: A Single-Center Experience. <i>Annals of Surgery</i> , 2001, 234, 149-164.	2.1	194
17	AN OPEN-LABEL, CONCENTRATION-RANGING TRIAL OF FK506 IN PRIMARY KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 1996, 62, 900-905.	0.5	193
18	Pancreatic Islet Cell Transplantation. <i>Surgical Clinics of North America</i> , 1978, 58, 365-382.	0.5	191

#	ARTICLE	IF	CITATIONS
19	THE IMMUNOPATHOLOGY OF CARDIAC XENOGRAFT REJECTION IN THE GUINEA PIG-TO-RAT MODEL. Transplantation, 1993, 56, 1-8.	0.5	188
20	Morbidity and mortality after living kidney donation, 1999-2001: survey of United States transplant centers. American Journal of Transplantation, 2003, 3, 830-4.	2.6	188
21	A molecular classifier for predicting future graft loss in late kidney transplant biopsies. Journal of Clinical Investigation, 2010, 120, 1862-1872.	3.9	179
22	Improved Scoring System to Assess Adult Donors For Cadaver Renal Transplantation. American Journal of Transplantation, 2003, 3, 715-721.	2.6	170
23	Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2015, 26, 1711-1720.	3.0	163
24	Causes of Renal Allograft Loss. Annals of Surgery, 1991, 214, 679-688.	2.1	162
25	Total or Near Total Pancreatectomy and Islet Autotransplantation for Treatment of Chronic Pancreatitis. Annals of Surgery, 1980, 192, 526-542.	2.1	160
26	Prednisone-Free Maintenance Immunosuppression-A 5-Year Experience. American Journal of Transplantation, 2005, 5, 2473-2478.	2.6	160
27	Nondirected Donation of Kidneys from Living Donors. New England Journal of Medicine, 2000, 343, 433-436.	13.9	155
28	Long-Term (20-37â€¦Years) Follow-Up of Living Kidney Donors. American Journal of Transplantation, 2002, 2, 959-964.	2.6	155
29	Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium. Transplantation, 2011, 91, 300-308.	0.5	151
30	DELAYED GRAFT FUNCTION IN THE ABSENCE OF REJECTION HAS NO LONG-TERM IMPACT. Transplantation, 1996, 61, 1331-1337.	0.5	150
31	Surgical Complications After Kidney Transplantation. Seminars in Dialysis, 2005, 18, 505-510.	0.7	146
32	Short- and Long-Term Outcomes of Kidney Transplants with Multiple Renal Arteries. Annals of Surgery, 1995, 221, 406-414.	2.1	135
33	The Ethics Statement of the Vancouver Forum on the Live Lung, Liver, Pancreas, and Intestine Donor. Transplantation, 2006, 81, 1386-1387.	0.5	130
34	ONE-YEAR FOLLOW-UP OF AN OPEN-LABEL TRIAL OF FK506 FOR PRIMARY KIDNEY TRANSPLANTATION1. Transplantation, 1996, 61, 1576-1581.	0.5	125
35	ASSOCIATION BETWEEN CYTOMEGALOVIRUS DISEASE AND CHRONIC REJECTION IN KIDNEY TRANSPLANT RECIPIENTS1. Transplantation, 1999, 68, 1879-1883.	0.5	125
36	THE IMPACT OF THE QUALITY OF INITIAL GRAFT FUNCTION ON CADAVER KIDNEY TRANSPLANTS1,2. Transplantation, 1994, 57, 812-815.	0.5	123

#	ARTICLE	IF	CITATIONS
37	The nondirected live-kidney donor: ethical considerations and practice guidelines. <i>Transplantation</i> , 2002, 74, 582-589.	0.5	123
38	Current thinking on chronic renal allograft rejection: Issues, concerns, and recommendations from a 1997 roundtable discussion. <i>American Journal of Kidney Diseases</i> , 1999, 33, 150-160.	2.1	119
39	Evolution of kidney, pancreas, and islet transplantation for patients with diabetes at the University of Minnesota. <i>American Journal of Surgery</i> , 1993, 166, 456-491.	0.9	118
40	Five preventable causes of kidney graft loss in the 1990s: A single-center analysis <sup>1</sup> . <i>Kidney International</i> , 2002, 62, 704-714.	2.6	117
41	2202 Kidney Transplant Recipients with 10 Years of Graft Function: What Happens Next?. <i>American Journal of Transplantation</i> , 2008, 8, 2410-2419.	2.6	115
42	Azathioprine Metabolism: Pharmacokinetics of 6-mercaptopurine, 6-thiouric Acid and 6-thioguanine Nucleotides in Renal Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 358-363.	1.0	113
43	Through a Glass Darkly. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 20-29.	3.0	112
44	Life satisfaction and adverse effects in renal transplant recipients: a longitudinal analysis. <i>Clinical Transplantation</i> , 2002, 16, 113-121.	0.8	108
45	Long-Term Deterioration of Kidney Allograft Function. <i>American Journal of Transplantation</i> , 2005, 5, 1405-1414.	2.6	107
46	Renal Function Profile in White Kidney Donors: The First 4 Decades. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2885-2893.	3.0	106
47	INTERACTION BETWEEN CYCLOSPORINE AND FLUCONAZOLE IN RENAL ALLOGRAFT RECIPIENTS. <i>Transplantation</i> , 1991, 51, 1014-1017.	0.5	104
48	IMMUNOLOGIC AND NONIMMUNOLOGIC FACTORS. <i>Transplantation</i> , 2000, 69, 54.	0.5	104
49	The Case for Living Kidney Sales: Rationale, Objections and Concerns. <i>American Journal of Transplantation</i> , 2004, 4, 2007-2017.	2.6	103
50	Twenty-Two Nondirected Kidney Donors: An Update on a Single Center's Experience. <i>American Journal of Transplantation</i> , 2004, 4, 1110-1116.	2.6	101
51	A Prospective Randomized Trial of Steroid-Free Maintenance Regimens in Kidney Transplant Recipients-An Interim Analysis. <i>American Journal of Transplantation</i> , 2005, 5, 1529-1536.	2.6	99
52	Predicting clinical outcome in the elderly renal transplant recipient. <i>Kidney International</i> , 2000, 57, 2144-2150.	2.6	98
53	Predictors of renal function following lung or heart-lung transplantation. <i>Kidney International</i> , 2002, 61, 2228-2234.	2.6	98
54	Rapid Discontinuation of Steroids in Living Donor Kidney Transplantation: A Pilot Study. <i>American Journal of Transplantation</i> , 2001, 1, 278-283.	2.6	93

#	ARTICLE	IF	CITATIONS
55	Outcome at 3 Years with a Prednisone-Free Maintenance Regimen: A Single-Center Experience with 349 Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2004, 4, 980-987.	2.6	93
56	Angiotensin II Blockade in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 320-327.	3.0	93
57	Seven Years Experience with Antilymphoblast Globulin for Renal Transplantation From Cadaver Donors. <i>Annals of Surgery</i> , 1976, 184, 352-368.	2.1	92
58	PROGRESSION OF KIDNEY DISEASE IN CHRONIC RENAL TRANSPLANT REJECTION. <i>Transplantation</i> , 1991, 52, 239-243.	0.5	91
59	Living Kidney Donor Follow-Up: State-of-the-Art and Future Directions, Conference Summary and Recommendations. <i>American Journal of Transplantation</i> , 2011, 11, 2561-2568.	2.6	91
60	PRE-EMPTIVE TRANSPLANTS FOR PATIENTS WITH RENAL FAILURE. <i>Transplantation</i> , 2000, 70, 625-631.	0.5	89
61	Pancreas after living donor kidney transplants in diabetic patients: impact on long-term kidney graft function. <i>Clinical Transplantation</i> , 2009, 23, 437-446.	0.8	88
62	Post-transplant malignant lymphoma. <i>American Journal of Medicine</i> , 1976, 61, 716-720.	0.6	87
63	Renal Transplantation in Infants. <i>Annals of Surgery</i> , 1990, 212, 353-367.	2.1	87
64	IMMUNOLOGIC FACTORS: THE MAJOR RISK FOR DECREASED LONG-TERM RENAL ALLOGRAFT SURVIVAL <sup>1,2</sup> . <i>Transplantation</i> , 1999, 68, 1842-1846.	0.5	87
65	A Multicenter Pilot Study of Early (4-Day) Steroid Cessation in Renal Transplant Recipients Under Simulect, Tacrolimus and Sirolimus. <i>American Journal of Transplantation</i> , 2005, 5, 157-166.	2.6	86
66	The Role of Procurement Biopsies in Acceptance Decisions for Kidneys Retrieved for Transplant. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 562-571.	2.2	85
67	Long-term Immunosuppression, Without Maintenance Prednisone, After Kidney Transplantation. <i>Annals of Surgery</i> , 2004, 240, 510-517.	2.1	84
68	Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2018, 4, e379.	0.8	84
69	FEATURES OF ACUTE REJECTION THAT INCREASE RISK FOR CHRONIC REJECTION <sup>1</sup> . <i>Transplantation</i> , 1999, 68, 1200-1203.	0.5	84
70	Kidney Transplants From Living Donors: How Donation Affects Family Dynamics. <i>Advances in Chronic Kidney Disease</i> , 1998, 5, 89-97.	2.2	83
71	Donor Scoring System for Cadaveric Renal Transplantation. <i>American Journal of Transplantation</i> , 2001, 1, 162-170.	2.6	82
72	Incentives for Organ Donation: Proposed Standards for an Internationally Acceptable System. <i>American Journal of Transplantation</i> , 2012, 12, 306-312.	2.6	81

#	ARTICLE	IF	CITATIONS
73	EVIDENCE THAT IMPROVED LATE RENAL TRANSPLANT OUTCOME CORRELATES WITH THE DEVELOPMENT OF IN VITRO DONOR ANTIGEN-SPECIFIC HYPOREACTIVITY. <i>Transplantation</i> , 1993, 55, 1017-1022.	0.5	79
74	HALF-LIFE AND RISK FACTORS FOR KIDNEY TRANSPLANT OUTCOME—IMPORTANCE OF DEATH WITH FUNCTION. <i>Transplantation</i> , 1993, 55, 757-760.	0.5	78
75	ORGAN DONATION IN THREE MAJOR AMERICAN CITIES WITH LARGE LATINO AND BLACK POPULATIONS. <i>Transplantation</i> , 1988, 46, 553-557.	0.5	76
76	Peri-operative cardiac morbidity in kidney transplant recipients: incidence and risk factors. <i>Clinical Transplantation</i> , 2001, 15, 154-158.	0.8	76
77	Living Donor Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1659-1669.	2.2	76
78	A PROSPECTIVE RANDOMIZED STUDY OF ACYCLOVIR VERSUS GANCICLOVIR PLUS HUMAN IMMUNE GLOBULIN PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION AFTER SOLID ORGAN TRANSPLANTATION <sup>1,2</sup> . <i>Transplantation</i> , 1994, 57, 876-883.	0.5	75
79	In defense of a regulated system of compensation for living donation. <i>Current Opinion in Organ Transplantation</i> , 2008, 13, 379-385.	0.8	75
80	Ten-Year Outcome after Rapid Discontinuation of Prednisone in Adult Primary Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 494-503.	2.2	75
81	Two Years Postconversion From a Prograf-Based Regimen to a Once-Daily Tacrolimus Extended-Release Formulation in Stable Kidney Transplant Recipients. <i>Transplantation</i> , 2007, 83, 1648-1651.	0.5	74
82	NPHP1 (Nephrocystin-1) Gene Deletions Cause Adult-Onset ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1772-1779.	3.0	74
83	Surrogate Markers for Long-Term Renal Allograft Survival. <i>American Journal of Transplantation</i> , 2004, 4, 1179-1183.	2.6	72
84	Emotional and Financial Experiences of Kidney Donors over the Past 50 Years. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2221-2231.	2.2	72
85	Prevention of Post-transplant Cardiovascular Disease - Report and Recommendations of an Ad Hoc Group <sup>1</sup> . <i>American Journal of Transplantation</i> , 2002, 2, 491-500.	2.6	71
86	Predictors of Graft Failure and Death in Elderly Kidney Transplant Recipients. <i>Transplantation</i> , 2013, 96, 1089-1096.	0.5	71
87	GAS-GENERATING SYSTEMS IN ACUTE RENAL ALLOGRAFT REJECTION IN THE RAT. <i>Transplantation</i> , 1996, 61, 93-98.	0.5	71
88	LIVING DONORS >55 YEARS. <i>Transplantation</i> , 1999, 67, 999-1004.	0.5	70
89	DELAYED ENDOCRINE PANCREAS GRAFT FUNCTION AFTER SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 1996, 61, 1323-1330.	0.5	68
90	Morbidity from Congenital Hepatic Fibrosis after Renal Transplantation for Autosomal Recessive Polycystic Kidney Disease. <i>American Journal of Transplantation</i> , 2002, 2, 360-365.	2.6	67

#	ARTICLE	IF	CITATIONS
91	ORGAN-SPECIFIC PATTERNS OF DONOR ANTIGEN-SPECIFIC HYPOREACTIVITY AND PERIPHERAL BLOOD ALLOGENEIC MICROCHIMERISM IN LUNG, KIDNEY, AND LIVER TRANSPLANT RECIPIENTS <sup>1</sup> . <i>Transplantation</i> , 1995, 60, 1546-1554.	0.5	66
92	Why We Should Develop a Regulated System of Kidney Sales: A Call for Action!: Table 1.. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 1129-1132.	2.2	63
93	CLINICAL DETERMINANTS OF MULTIPLE ACUTE REJECTION EPISODES IN KIDNEY TRANSPLANT RECIPIENTS <sup>1</sup> . <i>Transplantation</i> , 2000, 69, 2357-2360.	0.5	63
94	Genetic and Clinical Determinants of Early, Acute Calcineurin Inhibitor-Related Nephrotoxicity. <i>Transplantation</i> , 2012, 93, 624-631.	0.5	62
95	CYTOMEGALOVIRUS DISEASE RECURRENCE AFTER GANCICLOVIR TREATMENT IN KIDNEY AND KIDNEY-PANCREAS TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1999, 67, 94-97.	0.5	62
96	Recurrence of steroid-resistant nephrotic syndrome in kidney transplants is associated with increased acute renal failure and acute rejection. <i>Kidney International</i> , 1994, 45, 1440-1445.	2.6	60
97	Renal Transplantation for Patients 60 Years of Age or Older A Single-Institution Experience. <i>Annals of Surgery</i> , 1994, 220, 445-460.	2.1	60
98	Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications. <i>journal of applied laboratory medicine, The</i> , 2017, 2, 309-321.	0.6	59
99	EMPLOYMENT PATTERNS AFTER SUCCESSFUL KIDNEY TRANSPLANTATION <sup>1</sup> . <i>Transplantation</i> , 1996, 61, 729-733.	0.5	59
100	ALLOGRAFT RENAL VASCULAR THROMBOSIS-LACK OF INCREASE WITH CYCLOSPORINE IMMUNOSUPPRESSION. <i>Transplantation</i> , 1989, 47, 475-478.	0.5	58
101	Life satisfaction in renal transplant recipients: Preliminary results from the Transplant Learning Center. <i>American Journal of Kidney Diseases</i> , 2001, 38, 580-587.	2.1	58
102	Causes and timing of end-stage renal disease after living kidney donation. <i>American Journal of Transplantation</i> , 2018, 18, 1140-1150.	2.6	58
103	The Value of Needle Renal Allograft Biopsy I. A Retrospective Study of Biopsies Performed During Putative Rejection Episodes. <i>Annals of Surgery</i> , 1983, 197, 226-237.	2.1	57
104	RECURRENCE OF DISEASE IN PATIENTS RETRANSPLANTED FOR FOCAL SEGMENTAL GLOMERULOSCLEROSIS. <i>Transplantation</i> , 1992, 53, 755-757.	0.5	57
105	Complications by age in primary pediatric renal transplant recipients. <i>Pediatric Nephrology</i> , 1997, 11, 399-403.	0.9	57
106	KIDNEY TRANSPLANT RECIPIENTS WHO DIE WITH FUNCTIONING GRAFTS. <i>Transplantation</i> , 1996, 62, 1029,1030.	0.5	57
107	Simultaneous pancreas-kidney transplant versus kidney transplant alone in diabetic patients. <i>Kidney International</i> , 1992, 41, 924-929.	2.6	56
108	Posttransplant Diabetes Mellitus and Acute Rejection: Impact on Kidney Transplant Outcome. <i>Transplantation</i> , 2008, 85, 338-343.	0.5	55

#	ARTICLE	IF	CITATIONS
109	Chronic Progressive Calcineurin Nephrotoxicity: An Overstated Concept. American Journal of Transplantation, 2011, 11, 687-692.	2.6	55
110	LIVING UNRELATED DONORS IN KIDNEY TRANSPLANTS. Transplantation, 2000, 69, 1942-1945.	0.5	55
111	EVIDENCE THAT 15-DEOXYSPERGUALIN INHIBITS NATURAL ANTIBODY PRODUCTION BUT FAILS TO PREVENT HYPERACUTE REJECTION IN A DISCORDANT XENOGRAFT MODEL. Transplantation, 1992, 54, 26-31.	0.5	53
112	Pancreas after kidney transplants. American Journal of Surgery, 2001, 182, 155-161.	0.9	53
113	Pediatric Kidney Transplantation Using a Novel Protocol of Rapid (6-Day) Discontinuation of Prednisone: 2-Year Results. Transplantation, 2009, 88, 237-241.	0.5	53
114	Genetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantation. Transplantation, 2011, 91, 309-316.	0.5	52
115	Lethal complications of bilateral nephrectomy and splenectomy in hemodialyzed patients. American Journal of Surgery, 1975, 129, 616-620.	0.9	51
116	Urinary Î²2-Microglobulin Is Associated With Acute Renal Allograft Rejection. American Journal of Kidney Diseases, 2006, 47, 898-904.	2.1	50
117	BABESIOSIS AND HEMOPHAGOCYTIC SYNDROME IN AN ASPLENIC RENAL TRANSPLANT RECIPIENT. Transplantation, 1996, 62, 537-539.	0.5	50
118	COMPARISON OF IN VIVO AND IN VITRO IMMUNE RESPONSE TO PURIFIED HEPATOCYTES. Transplantation, 1990, 49, 429-435.	0.5	49
119	INCREASED INCIDENCE OF CARDIAC COMPLICATIONS IN KIDNEY TRANSPLANT RECIPIENTS WITH CYTOMEGALOVIRUS DISEASE. Transplantation, 2000, 70, 310-313.	0.5	48
120	Autotransplantation of Pancreatic Fragments to the Portal Vein and Spleen of Totally Pancreatectomized Dogs. Annals of Surgery, 1978, 187, 79-86.	2.1	47
121	Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics. Transplant International, 2013, 26, 982-989.	0.8	47
122	Evolution of Living Donor Nephrectomy at a Single Center. Transplantation, 2016, 100, 1299-1305.	0.5	47
123	Hypertension after kidney donation: Incidence, predictors, and correlates. American Journal of Transplantation, 2018, 18, 2534-2543.	2.6	47
124	Decreased Acute Rejection in Kidney Transplant Recipients Is Associated with Decreased Chronic Rejection. Annals of Surgery, 1999, 230, 493.	2.1	47
125	RISK FACTORS FOR SECOND RENAL ALLOGRAFTS IMMUNOSUPPRESSED WITH CYCLOSPORINE. Transplantation, 1991, 52, 253-258.	0.5	46
126	Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness. Clinical Pharmacology and Therapeutics, 2020, 108, 766-769.	2.3	46



#	ARTICLE	IF	CITATIONS
127	Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1047-1056.	0.8	43
128	Pretransplant Donor-Specific and Non-Specific Immune Parameters Associated With Early Acute Rejection. <i>Transplantation</i> , 2008, 85, 462-470.	0.5	43
129	The Relationships Between Cold Ischemia Time, Kidney Transplant Length of Stay, and Transplant-related Costs. <i>Transplantation</i> , 2019, 103, 401-411.	0.5	43
130	Thymoglobulin Versus ATGAM Induction Therapy in Pediatric Kidney Transplant Recipients: A Single-Center Report. <i>Transplantation</i> , 2005, 79, 958-963.	0.5	42
131	Design of a regulated system of compensation for living kidney donors. <i>Clinical Transplantation</i> , 2008, 22, 378-384.	0.8	41
132	Recurrent Glomerulonephritis Under Rapid Discontinuation of Steroids. <i>Transplantation</i> , 2011, 91, 1386-1391.	0.5	41
133	Longterm health-related quality of life after living liver donation. <i>Liver Transplantation</i> , 2016, 22, 53-62.	1.3	41
134	Molecular phenotype of kidney transplant indication biopsies with inflammation in scarred areas. <i>American Journal of Transplantation</i> , 2019, 19, 1356-1370.	2.6	41
135	PREGNANCY AFTER DONOR NEPHRECTOMY <sup>1,2</sup> . <i>Transplantation</i> , 1996, 62, 1934-1936.	0.5	41
136	GFR-estimating models in kidney transplant recipients on a steroid-free regimen. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1653-1661.	0.4	40
137	INFLUENCE OF CADAVER DONOR AGE ON THE SUCCESS OF KIDNEY TRANSPLANTS. <i>Transplantation</i> , 1981, 32, 532-534.	0.5	39
138	Cellular rejection in discordant xenografts when hyperacute rejection is prevented: analysis using adoptive and passive transfer. <i>Transplant Immunology</i> , 1994, 2, 87-93.	0.6	39
139	Pharmacokinetics of FK506 After Intravenous and Oral Administration in Patients Awaiting Renal Transplantation. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 859-864.	1.0	39
140	Impact of acute rejection on development of chronic rejection in pediatric renal transplant recipients. <i>Pediatric Transplantation</i> , 2000, 4, 92-99.	0.5	39
141	Late graft failure after kidney transplantation as the consequence of late versus early events. <i>American Journal of Transplantation</i> , 2018, 18, 1158-1167.	2.6	39
142	Larger nephron size, low nephron number, and nephrosclerosis on biopsy as predictors of kidney function after donating a kidney. <i>American Journal of Transplantation</i> , 2019, 19, 1989-1998.	2.6	39
143	Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial. <i>American Journal of Transplantation</i> , 2020, 20, 1039-1055.	2.6	39
144	Risk factors for chronic rejection - a clinical perspective. <i>Transplant Immunology</i> , 1998, 6, 1-11.	0.6	38

#	ARTICLE	IF	CITATIONS
145	Outcomes and Risk Factors for Graft Loss: Lessons Learned from 1,056 Pediatric Kidney Transplants at the University of Minnesota. <i>Journal of the American College of Surgeons</i> , 2017, 224, 473-486.	0.2	38
146	Persistent, Asymptomatic, Microscopic Hematuria in Prospective Kidney Donors. <i>Transplantation</i> , 2005, 80, 1425-1429.	0.5	37
147	Single-Nucleotide Polymorphisms, Acute Rejection, and Severity of Tubulitis in Kidney Transplantation, Accounting for Center-to-Center Variation. <i>Transplantation</i> , 2010, 90, 1401-1408.	0.5	37
148	Minimization of steroids in kidney transplantation. <i>Transplant International</i> , 2009, 22, 38-48.	0.8	36
149	The Unjustified Classification of Kidney Donors as Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1406-1413.	2.2	36
150	Quality of Life in Elderly Kidney Transplant Recipients. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 1877-1882.	1.3	36
151	A NEW IN VITRO APPROACH TO DETERMINE ACQUIRED TOLERANCE IN LONG-TERM KIDNEY ALLOGRAFT RECIPIENTS. <i>Transplantation</i> , 1990, 50, 783-789.	0.5	35
152	Kidney retransplants after initial graft loss to vascular thrombosis. <i>Clinical Transplantation</i> , 2001, 15, 6-10.	0.8	35
153	Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups. <i>American Journal of Transplantation</i> , 2019, 19, 2795-2804.	2.6	35
154	Renal transplantation for infantile cystinosis: Long-term follow-up. <i>Journal of Pediatric Surgery</i> , 1993, 28, 232-238.	0.8	34
155	Risk factors for chronic rejection in pediatric renal transplant recipients - a single-center experience. <i>Pediatric Nephrology</i> , 1997, 11, 395-398.	0.9	34
156	Graft Loss from Recurrent Glomerulonephritis Is Not Increased with a Rapid Steroid Discontinuation Protocol. <i>Transplantation</i> , 2006, 81, 214-219.	0.5	34
157	Long-term Outcomes for Living Pancreas Donors in the Modern Era. <i>Transplantation</i> , 2016, 100, 1322-1328.	0.5	34
158	The impact of cytomegalovirus infection 1 year after primary renal transplantation. <i>Clinical Transplantation</i> , 2010, 24, 572-577.	0.8	33
159	Antibody Removal by Column Immunoabsorption Prevents Tissue Injury in an Ex Vivo Model of Pig-to-Human Xenograft Hyperacute Rejection. <i>Journal of Surgical Research</i> , 1995, 59, 43-50.	0.8	32
160	Rapid Discontinuation of Prednisone in Higher-Risk Kidney Transplant Recipients. <i>Transplantation</i> , 2004, 78, 1397-1399.	0.5	32
161	Antithymocyte Globulin Induction in Living Donor Renal Transplant Recipients. <i>Transplantation</i> , 2012, 94, 331-337.	0.5	32
162	Validation of tacrolimus equation to predict troughs using genetic and clinical factors. <i>Pharmacogenomics</i> , 2012, 13, 1141-1147.	0.6	32

#	ARTICLE	IF	CITATIONS
163	Medication noncompliance: another iceberg's tip. <i>Transplantation</i> , 2004, 77, 776-778.	0.5	31
164	Multigene predictors of tacrolimus exposure in kidney transplant recipients. <i>Pharmacogenomics</i> , 2015, 16, 841-854.	0.6	31
165	Implications of excess weight on kidney donation: Long-term consequences of donor nephrectomy in obese donors. <i>Surgery</i> , 2018, 164, 1071-1076.	1.0	31
166	Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. <i>Clinical Transplantation</i> , 2018, 32, e13424.	0.8	30
167	ALG TREATMENT OF STEROID-RESISTANT REJECTION IN PATIENTS RECEIVING CYCLOSPORINE. <i>Transplantation</i> , 1986, 41, 579-582.	0.5	29
168	Renal transplantation for Type II diabetic patients compared with Type I diabetic patients and patients over 50 years old: a single-center experience. <i>Clinical Transplantation</i> , 2000, 14, 226-234.	0.8	29
169	GFR $\geq$ 25 years postdonation in living kidney donors with (vs. without) a first-degree relative with ESRD. <i>American Journal of Transplantation</i> , 2018, 18, 625-631.	2.6	29
170	Should I accept this kidney?. <i>Clinical Transplantation</i> , 2000, 14, 90-95.	0.8	28
171	Transplantation Using Marginal Living Donors. <i>American Journal of Kidney Diseases</i> , 2006, 47, 353-355.	2.1	28
172	Do inherited hypercoagulable states play a role in thrombotic events affecting kidney/pancreas transplant recipients?. <i>Clinical Transplantation</i> , 2007, 21, 32-37.	0.8	28
173	Should we pay donors to increase the supply of organs for transplantation? Yes. <i>BMJ: British Medical Journal</i> , 2008, 336, 1342-1342.	2.4	28
174	Rapid Discontinuation of Prednisone in Kidney Transplant Recipients. <i>Transplantation</i> , 2017, 101, 2590-2598.	0.5	28
175	Pseudorejection. <i>Annals of Surgery</i> , 1977, 186, 51-59.	2.1	27
176	Consideration of Donor Age and Human Leukocyte Antigen Matching in the Setting of Multiple Potential Living Kidney Donors. <i>Transplantation</i> , 2011, 92, 70-75.	0.5	27
177	Validation of single nucleotide polymorphisms associated with acute rejection in kidney transplant recipients using a large multi-center cohort. <i>Transplant International</i> , 2011, 24, 1231-1238.	0.8	27
178	Late Graft Loss After Kidney Transplantation: Is "Death With Function" Really Death With a Functioning Allograft?. <i>Transplantation</i> , 2020, 104, 1483-1490.	0.5	27
179	ASSESSMENT OF RENAL FUNCTION IN TYPE I DIABETIC PATIENTS AFTER KIDNEY, PANCREAS, OR COMBINED KIDNEY-PANCREAS TRANSPLANTATION. <i>Transplantation</i> , 1991, 51, 1184-1189.	0.5	26
180	Causes of kidney allograft loss in a large pediatric population at a single center. <i>Pediatric Nephrology</i> , 1994, 8, 57-61.	0.9	26

#	ARTICLE	IF	CITATIONS
181	Improved Late Graft Survival and Half-Lives in Pediatric Kidney Transplantation: A Single Center Experience. <i>American Journal of Transplantation</i> , 2002, 2, 939-945.	2.6	26
182	Predicting long-term kidney graft survival: can new trials be performed? <i>Transplantation</i> , 2003, 75, 1256-1259.	0.5	26
183	Positive remote crossmatch: impact on short-term and long-term outcome in cadaver renal transplantation. <i>Transplantation</i> , 2003, 75, 501-505.	0.5	26
184	Incentives for organ donation in the United States: feasible alternative or forthcoming apocalypse?. <i>Current Opinion in Organ Transplantation</i> , 2009, 14, 140-146.	0.8	26
185	The Impact of Donor Viral Replication at Transplant on Recipient Infections Posttransplant. <i>Transplantation</i> , 2015, 99, 602-608.	0.5	25
186	Islet transplantation using neonatal rat pancreata: Quantitative studies. <i>Journal of Surgical Research</i> , 1976, 20, 143-147.	0.8	24
187	PORTAL VERSUS SYSTEMIC TRANSPLANTATION OF DISPERSED NEONATAL PANCREAS. <i>Transplantation</i> , 1977, 24, 333-337.	0.5	24
188	Valganciclovir Administration to Kidney Donors to Reduce the Burden of Cytomegalovirus and Epstein-Barr Virus Transmission During Transplantation. <i>Transplantation</i> , 2015, 99, 1186-1191.	0.5	23
189	Reassessing Medical Risk in Living Kidney Donors. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1017-1019.	3.0	23
190	Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. <i>Pharmacogenomics</i> , 2018, 19, 175-184.	0.6	23
191	Decision support needs of kidney transplant candidates regarding the deceased donor waiting list: A qualitative study and conceptual framework. <i>Clinical Transplantation</i> , 2019, 33, e13530.	0.8	23
192	DL-ethionine Treatment of Adult Pancreatic Donors Amelioration of Diabetes in Multiple Recipients with Tissue From a Single Donor. <i>Annals of Surgery</i> , 1979, 189, 248-256.	2.1	22
193	CELL SUBSETS RESPONDING TO PURIFIED HEPATOCYTES AND EVIDENCE OF INDIRECT RECOGNITION OF HEPATOCYTE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I ANTIGEN. <i>Transplantation</i> , 1992, 53, 863-867.	0.5	22
194	Inhibition of the membrane attack complex of complement for induction of accommodation in the hamster-to-rat heart transplant model. <i>Xenotransplantation</i> , 2007, 14, 572-579.	1.6	22
195	Perioperative outcomes of cardiac surgery in kidney and kidney-pancreas transplant recipients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 133, 1212-1219.	0.4	22
196	Antihypertensive pharmacotherapy and long-term outcomes in pediatric kidney transplantation. <i>Clinical Transplantation</i> , 2013, 27, 472-480.	0.8	22
197	A Case-Based Analysis of Whether Living Related Donors Listed for Transplant Share ESRD Causes with Their Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 663-668.	2.2	22
198	SUCCESSFUL KIDNEY TRANSPLANTATION WITH CURRENT-SERA-NEGATIVE/HISTORICAL-SERA-POSTIVE T CELL CROSSMATCH. <i>Transplantation</i> , 1984, 37, 111-112.	0.5	21

#	ARTICLE	IF	CITATIONS
199	LOCAL IMMUNOSUPPRESSION WITH REDUCED SYSTEMIC TOXICITY IN A CANINE RENAL ALLOGRAFT MODEL. Transplantation, 1989, 48, 936-943.	0.5	21
200	PEDIATRIC RENAL TRANSPLANTSâ€™RESULTS WITH SEQUENTIAL IMMUNOSUPPRESSION <sup>1,2</sup> . Transplantation, 1992, 53, 46-51.	0.5	21
201	From First Principles - Tubulitis in Protocol Biopsies and Learning from History. American Journal of Transplantation, 2001, 1, 4-5.	2.6	21
202	Low birthweight and risk of albuminuria in living kidney donors. Clinical Transplantation, 2014, 28, 361-367.	0.8	21
203	Comparison of Cystatin C and Creatinine-Based Equations for GFR Estimation After Living Kidney Donation. Transplantation, 2014, 98, 871-877.	0.5	21
204	IMMUNOPATHOLOGICAL STUDIES OF THE RUPTURED HUMAN RENAL ALLOGRAFT. Transplantation, 1976, 22, 420-426.	0.5	20
205	Recurrent Membranoproliferative Glomerulonephritis Type 1 in Successive Renal Transplants. American Journal of Nephrology, 1987, 7, 143-149.	1.4	20
206	Combined liver and kidney transplantation. Transplant International, 1996, 9, 486-491.	0.8	20
207	Determinants of quality of life changes among long-term cardiac transplant survivors: results from longitudinal data. Journal of Heart and Lung Transplantation, 2003, 22, 1157-1167.	0.3	20
208	Appraisal of GFR-Estimating Equations Following Kidney Donation. American Journal of Kidney Diseases, 2009, 53, 1050-1058.	2.1	20
209	Differentially Expressed Gene Transcripts Using RNA Sequencing from the Blood of Immunosuppressed Kidney Allograft Recipients. PLoS ONE, 2015, 10, e0125045.	1.1	20
210	Long-term follow-up of the DeKAF cross-sectional cohort study. American Journal of Transplantation, 2019, 19, 1432-1443.	2.6	20
211	EVALUATION OF PRE- AND POSTTRANSPLANT DONOR-SPECIFIC TRANSFUSION/CYCLOSPORINE A IN NON-HLA IDENTICAL LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS. Transplantation, 1999, 68, 1117-1124.	0.5	20
212	SUCCESSFUL TRANSPLANTATION AFTER CONVERSION OF A POSITIVE CROSSMATCH TO NEGATIVE BY DISSOCIATION OF IgM ANTIBODY. Transplantation, 1989, 47, 127-129.	0.5	19
213	MIZORIBINE PHARMACOKINETICS AND PHARMACODYNAMICS IN A CANINE RENAL ALLOGRAFT MODEL OF LOCAL IMMUNOSUPPRESSION <sup>1,2</sup> . Transplantation, 1992, 53, 12-19.	0.5	19
214	The emergence of xenotransplantation. Transplant Immunology, 1995, 3, 21-31.	0.6	19
215	Stable Kidney Function in the Second Decade After Kidney Transplantation While on Cyclosporine-Based Immunosuppression. Transplantation, 2007, 83, 722-726.	0.5	19
216	Calcineurin inhibitors in HLA-identical living related donor kidney transplantation. Nephrology Dialysis Transplantation, 2014, 29, 209-218.	0.4	19

#	ARTICLE	IF	CITATIONS
217	Weight gain after kidney donation: Association with increased risks of type 2 diabetes and hypertension. <i>Clinical Transplantation</i> , 2018, 32, e13360.	0.8	19
218	Proposed guidelines for re-evaluation of patients on the waiting list for renal cadaver transplantation. <i>Transplantation</i> , 2002, 73, 811-812.	0.5	19
219	Successful renal transplantation in patients with prior history of malignancy. <i>American Journal of Medicine</i> , 1975, 59, 791-795.	0.6	18
220	CYCLOSPORIN A AS THE INITIAL IMMUNOSUPPRESSIVE AGENT FOR CANINE LUNG TRANSPLANTATION. <i>Transplantation</i> , 1982, 34, 372-375.	0.5	18
221	A Proposal for Cadaver Organ Procurement: Routine Removal with Right of Informed Refusal. <i>Journal of Health Politics, Policy and Law</i> , 1985, 10, 231-244.	0.9	18
222	Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder. <i>Clinical Transplantation</i> , 2016, 30, 60-65.	0.8	18
223	How patients choose kidney transplant centers: A qualitative study of patient experiences. <i>Clinical Transplantation</i> , 2019, 33, e13523.	0.8	18
224	Inflammation in areas of fibrosis: The DeKAF prospective cohort. <i>American Journal of Transplantation</i> , 2020, 20, 2509-2521.	2.6	18
225	Telomere Length of Recipients and Living Kidney Donors and Chronic Graft Dysfunction in Kidney Transplants. <i>Transplantation</i> , 2014, 97, 325-329.	0.5	18
226	TOTAL PANCREATECTOMY IN THE PIG FOR ISLET TRANSPLANTATION TECHNICAL ALTERNATIVES. <i>Transplantation</i> , 1991, 52, 11-14.	0.5	17
227	The role of monocytes and macrophages in delayed xenograft rejection. <i>Xenotransplantation</i> , 1997, 4, 40-48.	1.6	17
228	Payment for Living Kidney Donors (Vendors) Is Not an Abstract Ethical Discussion Occurring in a Vacuum. <i>American Journal of Transplantation</i> , 2004, 4, 1380-1381.	2.6	17
229	Living Donation: The Global Perspective. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 269-275.	0.6	17
230	The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure. <i>Kidney International</i> , 2014, 85, 404-415.	2.6	17
231	Post-transplant blood transfusions and pediatric renal allograft outcomes. <i>Pediatric Transplantation</i> , 2016, 20, 939-945.	0.5	17
232	Post-Transplant Malignancy after Pediatric Kidney Transplantation: Retrospective Analysis of Incidence and Risk Factors in 884 Patients Receiving Transplants Between 1963 and 2015 at the University of Minnesota. <i>Journal of the American College of Surgeons</i> , 2017, 225, 181-193.	0.2	17
233	Financial Burden Borne by Laparoscopic Living Kidney Donors. <i>Transplantation</i> , 2017, 101, 2253-2257.	0.5	17
234	Improved Outcomes of Kidney Transplantation in Infants (Age < 2 years). <i>Transplantation</i> , 2018, 102, 284-290.	0.5	17

#	ARTICLE	IF	CITATIONS
235	Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies. <i>Transplantation</i> , 2019, 103, 1131-1139.	0.5	17
236	Presumed consent for organ retrieval. <i>Theoretical Medicine and Bioethics</i> , 1984, 5, 155-166.	0.4	16
237	EVIDENCE THAT ZERO ANTIGEN-MATCHED CYCLOSPORINE-TREATED RENAL TRANSPLANT RECIPIENTS HAVE GRAFT SURVIVAL EQUAL TO THAT OF MATCHED RECIPIENTS. <i>Transplantation</i> , 1990, 49, 332-336.	0.5	16
238	CELL SUBSETS RESPONDING TO PURIFIED HEPATOCYTES AND EVIDENCE OF INDIRECT RECOGNITION OF HEPATOCYTE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I ANTIGEN. <i>Transplantation</i> , 1992, 53, 857-862.	0.5	16
239	CHRONIC RENAL ALLOGRAFT REJECTION IN THE FIRST 6 MONTHS POSTTRANSPLANT1,2. <i>Transplantation</i> , 1995, 60, 1413-1417.	0.5	16
240	Uric Acid and Allograft Loss From Interstitial Fibrosis/Tubular Atrophy. <i>Transplantation</i> , 2014, 97, 1066-1071.	0.5	16
241	Analysis of 75 Candidate SNPs Associated With Acute Rejection in Kidney Transplant Recipients: Validation of rs2910164 in MicroRNA MIR146A. <i>Transplantation</i> , 2019, 103, 1591-1602.	0.5	16
242	iHFTA and chronic active T cell-mediated rejection: A tale of 2 (DeKAF) cohorts. <i>American Journal of Transplantation</i> , 2021, 21, 1866-1877.	2.6	16
243	Outcomes of Living Kidney Donor Candidate Evaluations in the Living Donor Collective Pilot Registry. <i>Transplantation Direct</i> , 2021, 7, e689.	0.8	16
244	Liposomal formulation eliminates acute toxicity and pump incompatibility of parenteral cyclosporine. <i>Pharmaceutical Research</i> , 1989, 06, 601-607.	1.7	15
245	Transplant Kidneys Sooner: Discard Fewer Kidneys. <i>American Journal of Transplantation</i> , 2001, 1, 301-304.	2.6	15
246	Influence of the procurement surgeon on transplanted abdominal organ outcomes: An SRTR analysis to evaluate regional organ procurement collaboration. <i>American Journal of Transplantation</i> , 2019, 19, 2219-2231.	2.6	15
247	Kidney Transplantation in Children Younger Than 1 Year Using Cyclosporine Immunosuppression. <i>Annals of Surgery</i> , 1998, 228, 421-428.	2.1	15
248	THE USE OF CADAVER KIDNEYS FOR TRANSPLANTATION IN YOUNG CHILDREN. <i>Transplantation</i> , 1990, 50, 979-983.	0.5	14
249	The Importance of Innovative Efforts to Increase Organ Donation. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1691.	3.8	14
250	The impact of <sc>C</sc>4d and microvascular inflammation before we knew them. <i>Clinical Transplantation</i> , 2013, 27, 388-396.	0.8	14
251	Inflammation in the setting of chronic allograft dysfunction post-kidney transplant: phenotype and genotype. <i>Clinical Transplantation</i> , 2013, 27, 348-358.	0.8	14
252	Infection rates in tacrolimus versus cyclosporine-treated pediatric kidney transplant recipients on a rapid discontinuation of prednisone protocol: 1-year analysis. <i>Pediatric Transplantation</i> , 2017, 21, e12919.	0.5	14

#	ARTICLE	IF	CITATIONS
253	EVIDENCE THAT RAT XENOREACTIVE ANTIBODIES RECOGNIZE MULTIPLE PROTEIN ANTIGENS ON GUINEA PIG ENDOTHELIAL CELLS AND PLATELETS. <i>Transplantation</i> , 1994, 58, 458-466.	0.5	13
254	Impact of age on renal graft survival in children after the first rejection episode. <i>Pediatric Nephrology</i> , 1996, 10, 474-478.	0.9	13
255	IS THERE AN ASSOCIATION BETWEEN CYTOMEGALOVIRUS (CMV) AND RENAL ARTERY STENOSIS (RAS) IN KIDNEY TRANSPLANT RECIPIENTS?. <i>Transplantation</i> , 2000, 69, S386.	0.5	13
256	May-Thurner Syndrome in Renal Transplantation. <i>Transplantation</i> , 2001, 71, 698-702.	0.5	13
257	Plasma homocysteine levels in living kidney donors before and after uninephrectomy. <i>Translational Research</i> , 2004, 143, 340-343.	2.4	13
258	The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population. <i>American Journal of Transplantation</i> , 2019, 19, 2262-2273.	2.6	13
259	Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1387-1397.	2.2	13
260	Age alone is not a contraindication to kidney donation: Outcomes of donor nephrectomy in the elderly. <i>Clinical Transplantation</i> , 2018, 32, e13287.	0.8	13
261	What's New and What's Hot in Transplantation: Clinical Science ATC 2003. <i>American Journal of Transplantation</i> , 2003, 3, 1465-1473.	2.6	12
262	Human Leukocyte Antigen Type as a Risk Factor for Nonmelanomatous Skin Cancer in Patients after Renal Transplantation. <i>Transplantation</i> , 2004, 78, 775-778.	0.5	12
263	Death on the Kidney Waiting List—Good Candidates or Not?. <i>American Journal of Transplantation</i> , 2006, 6, 1953-1956.	2.6	12
264	Cystatin C Is Not Superior to Creatinine-Based Models in Estimating Glomerular Filtration Rate in Former Kidney Donors. <i>Transplantation</i> , 2007, 84, 1112-1117.	0.5	12
265	Media Appeals by Pediatric Patients for Living Donors and the Impact on a Transplant Center. <i>Transplantation</i> , 2011, 91, 593-596.	0.5	12
266	Gender Disparities and Financial Barriers to Living Kidney Donation. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1081-1083.	3.0	12
267	Financial burden associated with time to return to work after living kidney donation. <i>American Journal of Transplantation</i> , 2019, 19, 204-207.	2.6	12
268	Long-term psychosocial outcomes after nondirected donation: A single-center experience. <i>American Journal of Transplantation</i> , 2019, 19, 1498-1506.	2.6	12
269	KIDNEY TRANSPLANTATION WITHOUT A FINAL CROSSMATCH <sup>1,2</sup> . <i>Transplantation</i> , 1998, 66, 1835-1836.	0.5	12
270	IMPACT OF TRANSFUSIONS AND ACUTE REJECTION ON POSTTRANSPLANTATION DONOR ANTIGEN-SPECIFIC RESPONSES IN TWO STUDY POPULATIONS <sup>1,2</sup> . <i>Transplantation</i> , 1999, 67, 697-702.	0.5	12



#	ARTICLE	IF	CITATIONS
271	Amelioration of streptozotocin-induced diabetes in rats: Effect of islet isografts on plasma lipids and other metabolic abnormalities. <i>Metabolism: Clinical and Experimental</i> , 1979, 28, 489-494.	1.5	11
272	Prolongation of mouse and rat pancreatic islet cell allografts by adenosine deaminase inhibitors and adenine arabinoside. <i>Journal of Surgical Research</i> , 1980, 28, 44-48.	0.8	11
273	THE IMPACT OF HLA MATCHING ON GRAFT SURVIVAL. <i>Transplantation</i> , 1992, 54, 568.	0.5	11
274	Living or deceased donor kidney transplants for candidates with significant extrarenal morbidity. <i>Clinical Transplantation</i> , 2006, 20, 346-350.	0.8	11
275	Kidney Donation and Risk of ESRD. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 92.	3.8	11
276	Kidney donor outcomes 5 years after donation. <i>Clinical Transplantation</i> , 2019, 33, e13657.	0.8	11
277	Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing. <i>Pharmacogenomics Journal</i> , 2019, 19, 375-389.	0.9	11
278	Predictors of Survival After Liver Transplantation in Patients With the Highest Acuity (MELD $\leq$ 40). <i>Annals of Surgery</i> , 2020, 272, 458-466.	2.1	11
279	Long-Term Living Kidney Donor Risk: A Web-Based Calculator. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2968-2969.	3.0	11
280	MOUSE-TO-RABBIT XENOTRANSPLANTATION. <i>Transplantation</i> , 1999, 67, 360-365.	0.5	11
281	EFFECT OF AN ADENOSINE DEAMINASE INHIBITOR ON SURVIVAL OF MOUSE PANCREATIC ISLET ALLOGRAFTS. <i>Transplantation</i> , 1979, 27, 355-357.	0.5	10
282	Cold storage preservation of islet and pancreas grafts as assessed by in vivo function after transplantation to diabetic hosts. <i>Cryobiology</i> , 1983, 20, 138-150.	0.3	10
283	En bloc simultaneous pancreas and kidney allotransplantation in the pig. <i>Journal of Surgical Research</i> , 1990, 49, 366-370.	0.8	10
284	Pretransplant Exposure to Donor HLA-DR Antigen in Random Transfusion Units and the Development of Donor Antigen-Specific Hyporeactivity. <i>Human Immunology</i> , 1997, 55, 148-153.	1.2	10
285	What's special about the ethics of living donors? Reply to Ross et al.. <i>Transplantation</i> , 2002, 74, 421-422.	0.5	10
286	Kidney Transplant Half-Life ( $t_{1/2}$ ) After Rapid Discontinuation of Prednisone. <i>Transplantation</i> , 2009, 87, 100-102.	0.5	10
287	Optimal Cutoff Point for Immunoperoxidase Detection of C4d in the Renal Allograft: Results From a Multicenter Study. <i>Transplantation</i> , 2010, 90, 1099-1105.	0.5	10
288	Cystatin C Enhances Glomerular Filtration Rate Estimating Equations in Kidney Transplant Recipients. <i>American Journal of Nephrology</i> , 2014, 39, 59-65.	1.4	10

#	ARTICLE	IF	CITATIONS
289	Renal transplantation. <i>Academic Radiology</i> , 1995, 2, 159-166.	1.3	9
290	Steroid Elimination—Who, When, How?. <i>Transplantation Proceedings</i> , 2008, 40, S52-S56.	0.3	9
291	Validation of genetic variants associated with early acute rejection in kidney allograft transplantation. <i>Clinical Transplantation</i> , 2012, 26, 418-423.	0.8	9
292	Outcome of living kidney donors left with multiple renal arteries. <i>Clinical Transplantation</i> , 2012, 26, E7-11.	0.8	9
293	Graft loss due to recurrent disease in pediatric kidney transplant recipients on a rapid prednisone discontinuation protocol. <i>Pediatric Transplantation</i> , 2012, 16, 704-710.	0.5	9
294	Increased ESRD and mortality risk for kidney donors?. <i>Nature Reviews Nephrology</i> , 2014, 10, 130-131.	4.1	9
295	Measured Glomerular Filtration Rate After Kidney Donation: No Evidence of Accelerated Decay. <i>Transplantation</i> , 2018, 102, 1756-1761.	0.5	9
296	Outcome of renal transplantation or dialysis in patients with a history of renal cancer. <i>Cancer</i> , 1992, 70, 1564-1567.	2.0	8
297	Reply to “Genetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantation”. <i>Transplantation</i> , 2012, 93, e41-e42.	0.5	8
298	Kidney donors at increased risk? Additional studies are needed. <i>Kidney International</i> , 2014, 86, 650.	2.6	8
299	Medical outcomes of adolescent live kidney donors. <i>Pediatric Transplantation</i> , 2014, 18, 336-341.	0.5	8
300	Moving Beyond Minimization Trials in Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2898-2901.	3.0	8
301	Return to normal activities and work after living donor laparoscopic nephrectomy. <i>Clinical Transplantation</i> , 2017, 31, e12862.	0.8	8
302	Incidence and magnitude of posttransplant cardiovascular disease after pediatric kidney transplantation: Risk factor analysis of 1058 pediatric kidney transplants at the university of Minnesota. <i>Pediatric Transplantation</i> , 2018, 22, e13283.	0.5	8
303	Medication adherence is associated with an increased risk of cancer in kidney transplant recipients: a cohort study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 364-370.	0.4	8
304	Comparing Pretransplant and Posttransplant Outcomes When Choosing a Transplant Center: Focus Groups and a Randomized Survey. <i>Transplantation</i> , 2020, 104, 201-210.	0.5	8
305	Increased Serum Creatinine Resulting from Hyperglycemia, Mimicking Transplant Rejection. <i>Annals of Internal Medicine</i> , 1975, 83, 519.	2.0	8
306	Kidney donation and chronic kidney disease. <i>Minnesota Medicine</i> , 2012, 95, 55-7.	0.1	8

#	ARTICLE	IF	CITATIONS
307	A MOUSE MODEL OF ISLET TRANSPLANTATION USING NEONATAL DONORS. <i>Transplantation</i> , 1977, 24, 389-392.	0.5	7
308	Timing of cyclosporine administration in patients with delayed graft function. <i>Journal of Surgical Research</i> , 1987, 43, 489-494.	0.8	7
309	Prednisone-free maintenance immunosuppression in obese kidney transplant recipients. <i>Clinical Transplantation</i> , 2019, 33, e13668.	0.8	7
310	Outcomes of Kidney Donors With Impaired Fasting Glucose. <i>Transplantation</i> , 2022, 106, 138-146.	0.5	7
311	Outcomes of Hypertensive Kidney Donors Using Current and Past Hypertension Definitions. <i>Kidney International Reports</i> , 2021, 6, 1242-1253.	0.4	7
312	Intermediate Renal Outcomes, Kidney Failure, and Mortality in Obese Kidney Donors. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2933-2947.	3.0	7
313	SYNERGISTIC EFFECT OF DONOR-SPECIFIC SOLUBLE MEMBRANE ANTIGEN INJECTION AND ANTITHYMOCYTE SERUM ADMINISTRATION ON THE SURVIVAL OF ISLET ALLOGRAFTS IN RATS. <i>Transplantation</i> , 1978, 25, 336-338.	0.5	6
314	ENCEPHALOMYOCARDITIS VIRUS-INDUCED DIABETES MELLITUS TREATED BY ISLET TRANSPLANTATION. <i>Transplantation</i> , 1979, 27, 200-202.	0.5	6
315	TREATMENT OF RENAL TRANSPLANT REJECTION EPISODES IN PATIENTS RECEIVING PREDNISONE AND AZATHIOPRINE. <i>Transplantation</i> , 1985, 40, 35-38.	0.5	6
316	SUCCESSFUL TRANSPLANTATION OF HIGHLY SENSITIZED PATIENTS WITHOUT REGARD TO HLA MATCHING. <i>Transplantation</i> , 1988, 45, 338-341.	0.5	6
317	Role of macrophages in the immune response to hepatocytes. <i>Journal of Surgical Research</i> , 1990, 48, 568-572.	0.8	6
318	Iliac artery stenosis masquerading as diuretic resistant congestive heart failure. <i>Clinical Transplantation</i> , 2000, 14, 11-13.	0.8	6
319	Risk factors for rising creatinine in renal allografts with 1 and 3-yr survival. <i>Clinical Transplantation</i> , 2006, 20, 667-672.	0.8	6
320	Must All Living Donor Compensation Be Viewed as Valuable Consideration?. <i>American Journal of Transplantation</i> , 2007, 7, 1309-1310.	2.6	6
321	Urinary Peptide Patterns in Native Kidneys and Kidney Allografts. <i>Transplantation</i> , 2009, 87, 1807-1813.	0.5	6
322	Steroid minimization for sirolimus-treated renal transplant recipients. <i>Clinical Transplantation</i> , 2011, 25, 457-467.	0.8	6
323	Transplantation of solid organ recipients shedding Epstein-Barr virus <scp>DNA</scp> pre-transplant: A prospective study. <i>Clinical Transplantation</i> , 2017, 31, e13116.	0.8	6
324	Long-term outcomes of pediatric kidney transplant recipients with a pretransplant malignancy. <i>Pediatric Transplantation</i> , 2019, 23, e13557.	0.5	6

#	ARTICLE	IF	CITATIONS
325	Incidence, risk factors, and long-term outcomes associated with antibody-mediated rejection in The long-term Deterioration of Kidney Allograft Function (DeKAF) prospective cohort study. <i>Clinical Transplantation</i> , 2021, 35, e14337.	0.8	6
326	Development of a Patient-specific Search of Transplant Program Outcomes and Characteristics: Feedback From Kidney Transplant Patients. <i>Transplantation Direct</i> , 2020, 6, e585.	0.8	6
327	Combined liver and kidney transplantation. <i>Transplant International</i> , 1996, 9, 486-491.	0.8	6
328	Kidney and pancreas transplantation without a crossmatch in select circumstances - it can be done. <i>Clinical Transplantation</i> , 2001, 15, 236-239.	0.8	5
329	Resolved: In Minimizing Kidney Transplant Immunosuppression, Steroids Should Go before Calcineurin Inhibitors: Pro. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 3026-3030.	3.0	5
330	Selection of Controls in Kidney Donor Outcome Studies: An Admirable Effort. <i>American Journal of Kidney Diseases</i> , 2013, 61, 194-196.	2.1	5
331	Rapid discontinuation of prednisone in kidney transplant recipients from at-risk subgroups: an OPTN/SRTR analysis. <i>Transplant International</i> , 2020, 33, 181-201.	0.8	5
332	A regulated system of incentives for living kidney donation: Clearing the way for an informed assessment. <i>American Journal of Transplantation</i> , 2022, 22, 2509-2514.	2.6	5
333	LIVER CYSTS IN STREPTOZOTOCIN-TREATED RATS. <i>Transplantation</i> , 1977, 24, 162-163.	0.5	4
334	When Should the Third Renal Transplant Rejection Episode be Treated?. <i>Annals of Surgery</i> , 1977, 186, 104-110.	2.1	4
335	Surgical Problems in Immunodeficient and Immunosuppressed Children. <i>Surgical Clinics of North America</i> , 1979, 59, 213-221.	0.5	4
336	Noncompliance and late graft loss: Implications for long-term clinical studies. <i>Transplantation Reviews</i> , 1999, 13, 78-82.	1.2	4
337	Long-term follow-up of living kidney donors. <i>Current Opinion in Organ Transplantation</i> , 2000, 5, 319-323.	0.8	4
338	Steroid-free Maintenance Immunosuppression and ABO-incompatible Transplantation. <i>Transplantation</i> , 2010, 89, 648-649.	0.5	4
339	A Regulated System of Incentives for Living Kidney Donation: It Is Time for Opposing Groups to Have a Meaningful Dialogue!. <i>American Journal of Transplantation</i> , 2014, 14, 1944-1945.	2.6	4
340	The Rationale for Incentives for Living Donors: An International Perspective?. <i>Current Transplantation Reports</i> , 2015, 2, 44-51.	0.9	4
341	Little effect of state policies on organ donation in the USA. <i>Nature Reviews Nephrology</i> , 2015, 11, 570-572.	4.1	4
342	Ethical review of the responsibilities of the patient advocate in living donor liver transplant. <i>Clinical Liver Disease</i> , 2016, 7, 57-59.	1.0	4

#	ARTICLE	IF	CITATIONS
343	Concepts of Genomics in Kidney Transplantation. <i>Current Transplantation Reports</i> , 2017, 4, 116-123.	0.9	4
344	Enteric Conversion of Bladder-drained Pancreas as a Predictor of Outcomes in Almost 600 Recipients at a Single Center. <i>Transplantation Direct</i> , 2020, 6, e550.	0.8	4
345	Re-hospitalization after pediatric kidney transplant: A single-center study. <i>Pediatric Transplantation</i> , 2020, 24, e13717.	0.5	4
346	Premature Death in Kidney Transplant Recipients: The Time for Trials is Now. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 665-673.	3.0	4
347	Pre-kidney Donation Pregnancy Complications and Long-term Outcomes. <i>Transplantation</i> , 2022, Publish Ahead of Print, .	0.5	4
348	LOCAL PREDNISOLONE INFUSION OF CANINE RENAL ALLOGRAFTS. <i>Transplantation</i> , 1989, 48, 1072-1074.	0.5	3
349	Promotion of Altruistic Donation: A Reply. <i>Transplantation</i> , 2010, 89, 902-903.	0.5	3
350	The case for a regulated system of incentives for living kidney donation. <i>Annals of the Royal College of Surgeons of England</i> , 2011, 93, 188-190.	0.3	3
351	Living donor kidney allograft survival at 50 years. <i>Clinical Transplantation</i> , 2017, 31, e12938.	0.8	3
352	Induction type and outcomes for kidney graft and patient survival in recipients with prior lung transplantation in the United States. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 157-164.	0.3	3
353	Pharmacogenomics in kidney transplant recipients and potential for integration into practice. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1457-1465.	0.7	3
354	Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1035-1044.	1.0	3
355	Outcomes of Kidney Allograft and Recipient Survival After Liver Transplantation by Induction Type in the United States. <i>Liver Transplantation</i> , 2021, 27, 1553-1562.	1.3	3
356	RETRANSPLANTATION AFTER RENAL ALLOGRAFT LOSS DUE TO NONCOMPLIANCE <sup>1,2</sup> . <i>Transplantation</i> , 1995, 59, 467-471.	0.5	3
357	Removal Of Baboon And Human Antiporcine Igg And Igm Natural Antibodies By Immunoabsorption. <i>Transplantation</i> , 1995, 59, 294-299.	0.5	3
358	Pretransplant sensitization with major histocompatibility complex class I+ class II <sup>+</sup> hepatocytes leads to accelerated skin graft rejection. <i>Journal of Surgical Research</i> , 1992, 53, 182-187.	0.8	2
359	Is MHC matching as a primary criterion in kidney allocation justified?. <i>Nature Genetics</i> , 1993, 5, 211-213.	9.4	2
360	Risks versus benefits of living kidney donation. <i>Current Opinion in Organ Transplantation</i> , 2003, 8, 155-159.	0.8	2

#	ARTICLE	IF	CITATIONS
361	The high cost of organ transplant commercialism. <i>Kidney International</i> , 2014, 86, 858-859.	2.6	2
362	Increasing the use of available deceased donor kidneys. <i>Nature Reviews Urology</i> , 2016, 13, 500-501.	1.9	2
363	Delivery of transplant care among Hmong kidney transplant recipients: Outcomes from a single institution. <i>Clinical Transplantation</i> , 2019, 33, e13539.	0.8	2
364	Risk of kidney disease after living kidney donation. <i>Nature Reviews Nephrology</i> , 2021, 17, 509-510.	4.1	2
365	Early Steroid Cessation After Kidney Transplant. <i>JAMA Surgery</i> , 2021, 156, 314.	2.2	2
366	A Regulated System of Incentives for Kidney Donation—Time for a Trial!. <i>JAMA Surgery</i> , 2021, 156, 807.	2.2	2
367	THE HISTORY OF THE CONCEPT OF BRAIN DEATH AND ORGAN PRESERVATION. , 2003, , 64-75.		2
368	Correlation of Glomerular Size With Donor-recipient Factors and With Response to Injury. <i>Transplantation</i> , 2020, Publish Ahead of Print, 2451-2460.	0.5	2
369	Steroid-free immunosuppression in kidney transplant recipients: the University of Minnesota experience. <i>Clinical Transplants</i> , 2007, , 43-50.	0.2	2
370	Beyond Hyperacute Rejection. <i>Transplantation</i> , 1995, 59, 171-176.	0.5	2
371	THE EFFECT OF THE REFERRING DIALYSIS CENTER ON RENAL TRANSPLANT RESULTS. <i>Transplantation</i> , 1988, 45, 894-898.	0.5	1
372	A Unique Presentation of an Anastomotic Pseudoaneurysm-Case Report. <i>Vascular Surgery</i> , 1991, 25, 131-135.	0.3	1
373	WHY STUDY KIDNEY TRANSPLANT RISK FACTORS?. <i>Transplantation</i> , 2003, 75, 266-267.	0.5	1
374	Risk Factors for Developing Adult Cardiovascular Disease in Children Who Received a Kidney Transplant: Analysis of 1,055 Kidney Transplants between 1963-2015 at a Single Institution. <i>Journal of the American College of Surgeons</i> , 2016, 223, S148-S149.	0.2	1
375	The clinical implications of the unique glomerular complement deposition pattern in transplant glomerulopathy. <i>Journal of Nephrology</i> , 2018, 31, 157-164.	0.9	1
376	Pediatric retransplantation of the liver: A prognostic scoring tool. <i>Pediatric Transplantation</i> , 2020, 24, e13775.	0.5	1
377	Organ Donation After Euthanasia. <i>JAMA Surgery</i> , 2020, 155, 924.	2.2	1
378	End-stage Renal Disease After Kidney Donation—More Research Needed. <i>JAMA Surgery</i> , 2020, 155, e195473.	2.2	1

#	ARTICLE	IF	CITATIONS
379	The family voucher program: A 50-year simulation. American Journal of Transplantation, 2021, 21, 1350-1351.	2.6	1
380	Donor Scoring System for Cadaveric Renal Transplantation. American Journal of Transplantation, 2001, 1, 162.	2.6	1
381	Nondirected, Advanced, and Voucher-Based Donation—The Importance of Terminology. JAMA Surgery, 2022, 157, 280.	2.2	1
382	DONOR PARAMETERS PREDICT EARLY GRAFT OUTCOME AFTER CADAVERIC RENAL TRANSPLANTATION.. Transplantation, 2000, 69, S263.	0.5	0
383	Patient-Initiated Request for Donation Information. AMA Journal of Ethics, 2005, 7, 589.	0.4	0
384	Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients. Canadian Journal of Infectious Diseases and Medical Microbiology, 2020, 2020, 1-12.	0.7	0
385	Risk Prediction for Delayed Allograft Function. Transplantation, 2021, Publish Ahead of Print, .	0.5	0
386	Novel Phenotypes for Acute Kidney Transplant Rejection Using Semi-Supervised Clustering. Journal of the American Society of Nephrology: JASN, 2021, 32, 2387-2388.	3.0	0
387	Ethics of Paid Living-Unrelated Donation. , 2008, , 417-429.		0
388	Long-Term Outcomes for the Donor. , 2008, , 87-100.		0
389	Live Donor Transplantation. , 2014, , 75-84.		0
390	LIVING DONOR TRANSPLANTATION. , 1997, , 53-60.		0
391	Reduced Cell Infiltration in Hearts from TNF-??R or IL-1R knockout mice transplanted into rats.. Transplantation, 1999, 67, S554.	0.5	0
392	KIDNEY TRANSPLANT USING PEDIATRIC DONORS-EFFECT ON LONG TERM GRAFT AND PATIENT SURVIVAL RATES. Transplantation, 1999, 67, S575.	0.5	0
393	ADMINISTRATION OF OKT3 AS A TWO-HOUR INFUSION DOES NOT ATTENUATE FIRST-DOSE SIDE EFFECTS. Transplantation, 1999, 68, 709-710.	0.5	0
394	ANTIBODY-MEDIATED REJECTION OF AN HLA-IDENTICAL, ABO-INCOMPATIBLE KIDNEY TRANSPLANT AFTER TWO FAILED CADAVER TRANSPLANTS. Transplantation, 1994, 58, 723-724.	0.5	0